Beta
Emtricitabine/tenofovir disoproxil and other oral antiretrovirals
medication Under reviewEmtricitabine/tenofovir disoproxil fumarate (often abbreviated FTC/TDF) is an oral fixed‑dose combination of two nucleos(t)ide reverse‑transcriptase inhibitors originally developed for the treatment of HIV infection and now widely used for HIV pre‑exposure prophylaxis (PrEP) in HIV‑negative but high‑risk individuals. Emtricitabine is a cytidine analog and tenofovir disoproxil fumarate is a prodrug of tenofovir, an adenosine monophosphate analog; both act as chain terminators during viral DNA synthesis. After oral administration, tenofovir disoproxil fumarate is converted to tenofovir and then phosphorylated intracellularly to tenofovir diphosphate, while emtricitabine is phosphorylated to emtricitabine triphosphate. These active metabolites competitively inhibit HIV reverse transcriptase and become incorporated into viral DNA, preventing further elongation. In healthy HIV‑negative people using the drug as PrEP, the clinical application is near‑complete prevention of sexually acquired HIV when taken consistently, with established dosing regimens for daily and, in some settings, event‑driven use. Beyond HIV prevention, prolonged use in healthy individuals has been studied for systemic safety, including effects on kidney function, bone mineral density, liver parameters, and mitochondrial function. Most data indicate good overall tolerability, but emerging evidence suggests that long‑term exposure may induce subclinical mitochondrial changes and oxidative stress in otherwise healthy adults.
Research summary
The scientific evidence for emtricitabine/tenofovir disoproxil fumarate in healthy humans is extensive, driven largely by large randomized trials and pooled observational cohorts evaluating PrEP. Multiple studies in seronegative men and women at high risk for HIV show that daily FTC/TDF dramatically reduces HIV incidence when adherence is high, with very low rates of serious clinical adverse events over follow‑up periods up to several years. Pharmacokinetic work in healthy volunteers demonstrates that the fixed‑dose combination is bioequivalent to the individual drugs and that coadministration does not meaningfully alter exposure. Safety research in healthy PrEP users finds small average declines in bone mineral density and mild changes in renal biomarkers, but clinically significant kidney or bone events are rare in the short to medium term. More recent mechanistic work in healthy adults on PrEP has identified mitochondrial dysfunction and increased markers of oxidative stress after 12 months of FTC/TDF, indicating that long‑term use is not entirely without biological cost even when overt symptoms are minimal. Overall, the consensus is that FTC/TDF is highly effective and generally well tolerated for HIV prevention in healthy people, with a growing recognition of subtle chronic effects that warrant monitoring.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Emtricitabine/tenofovir disoproxil and other oral antiretrovirals to your stack to report effects
Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
Schwarz UI, Labbé L, Turgeon J, et al.
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
Núñez M, Soriano V.
No reports yet
Be the first to report this effect and help the community.
Add Emtricitabine/tenofovir disoproxil and other oral antiretrovirals to your stack to report effects
Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis Safe?
Corneli A, McKenna K, Ryan R, et al.
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate in Cisgender Women: A Pooled Analysis of Effectiveness and Safety
Spinelli MA, Glidden DV, Liu AY, et al.
Reported Side Effects
No reports yet
Be the first to report this effect and help the community.
Add Emtricitabine/tenofovir disoproxil and other oral antiretrovirals to your stack to report effects
Liver and renal safety of tenofovir disoproxil fumarate in HBeAg-negative chronic hepatitis B patients: a 96-week study
Kim HJ, Park JY, Kim DY, et al.
Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis Safe?
Corneli A, McKenna K, Ryan R, et al.
No reports yet
Be the first to report this effect and help the community.
Add Emtricitabine/tenofovir disoproxil and other oral antiretrovirals to your stack to report effects
Mitochondrial Disorders After 12 Months of Human Immunodeficiency Virus Type 1 Preexposure Prophylaxis Based on Tenofovir Disoproxil Fumarate Plus Emtricitabine in Healthy Adults.
Morelli M, Chiarantini E, Bargagli E, et al.
No reports yet
Be the first to report this effect and help the community.
Add Emtricitabine/tenofovir disoproxil and other oral antiretrovirals to your stack to report effects
Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis Safe?
Corneli A, McKenna K, Ryan R, et al.
Research (6 studies)
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate in Cisgender Women: A Pooled Analysis of Effectiveness and Safety
Spinelli MA, Glidden DV, Liu AY, et al.
Mitochondrial Disorders After 12 Months of Human Immunodeficiency Virus Type 1 Preexposure Prophylaxis Based on Tenofovir Disoproxil Fumarate Plus Emtricitabine in Healthy Adults.
Morelli M, Chiarantini E, Bargagli E, et al.
Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis Safe?
Corneli A, McKenna K, Ryan R, et al.
Liver and renal safety of tenofovir disoproxil fumarate in HBeAg-negative chronic hepatitis B patients: a 96-week study
Kim HJ, Park JY, Kim DY, et al.
Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
Schwarz UI, Labbé L, Turgeon J, et al.
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
Núñez M, Soriano V.
Community updates
No updates yet for this supplement.
Be the first to share your experience!